Linda Wang
- Late-breaking abstract: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: The LANTERN studyBy Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Francesco Patalano, Michael Humphries, Linda Wang and Donald BanerjiNanshan Zhong1Department of Respiratory Medicine, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital , Guangzhou Medical University, Guangzhou, Guangdong, ChinaChangzheng Wang2Institute of Respiratory Disease, Xin Qiao Hospital, Third Military Medical University, Chongqing City, Chongqing, ChinaXiangdong Zhou3Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing City, Chongqing, ChinaNuofu Zhang1Department of Respiratory Medicine, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital , Guangzhou Medical University, Guangzhou, Guangdong, ChinaFrancesco Patalano4Primary Care, Novartis Pharma AG, Basel, SwitzerlandMichael Humphries5Primary Care, Beijing Novartis Pharma Co. Ltd., Shanghai, ChinaLinda Wang5Primary Care, Beijing Novartis Pharma Co. Ltd., Shanghai, ChinaDonald Banerji6Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Evaluation of omalizumab therapy in a Chinese versus predominantly Caucasian population: Comparison of clinical dataBy Jing Yang, Michael Humphries, Shuang Ren, Linda Wang, Abhijit Pethe and Ioannis KottakisJing Yang1Respiratory Franchise, Beijing Novartis Pharma Co. Ltd., Beijing, ChinaMichael Humphries1Respiratory Franchise, Beijing Novartis Pharma Co. Ltd., Beijing, ChinaShuang Ren2DMPK, Novartis Institutes for Biomedical Research, Shanghai, ChinaLinda Wang1Respiratory Franchise, Beijing Novartis Pharma Co. Ltd., Beijing, ChinaAbhijit Pethe3Integrated Information Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, IndiaIoannis Kottakis4DF Respiratory Xolair, Novartis Pharma AG, Basel, Switzerland
- Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN studyBy Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Francesco Patalano, Michael Humphries, Linda Wang and Donald BanerjiNanshan Zhong1State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, ChinaChangzheng Wang2Institute of Respiratory Disease, Xin Qiao Hospital, Third Military Medical University, Chongqing City, ChinaXiangdong Zhou3Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing City, ChinaNuofu Zhang1State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, ChinaFrancesco Patalano4Respiratory, Novartis Pharma AG, Basel, SwitzerlandMichael Humphries5Respiratory, Beijing Novartis Pharma Co. Ltd., Shanghai, SwitzerlandLinda Wang5Respiratory, Beijing Novartis Pharma Co. Ltd., Shanghai, SwitzerlandDonald Banerji6Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.